FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL - Summary - MDSpire
Clinical Guidelines

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

The CAR T-cell therapy brexucabtagene autoleucel (Tecartus) was issued full approval for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The approval now includes efficacy, safe...

Share

The FDA has granted full approval to brexucabtagene autoleucel (Tecartus) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) based on positive outcomes from the ZUMA-2 study. This therapy demonstrated high response rates and durable efficacy, especially in patients who are naive to BTK inhibitors. The approval fulfills postmarketing requirements and enhances treatment strategies for MCL, which predominantly affects older men. With 33,000 new diagnoses annually, this approval signifies significant progress in MCL management.

Original Source(s)

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

  • by The ASCO Post Staff

  • April 3, 2026

Related Content

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

Turning Proteins into DNA for Ultra-Sensitive Sequencing

Stanford researchers repurpose DNA sequencing technology to read proteins at single-molecule resolution, complementing – and potentially surpassing – mass spectrometry

  • April 2, 2026

  • 2 min